华东医药股份有限公司 2018 年第三季度报告正文 | | | 华东医药股份有限公司 2018 年第三季度报告正文 1 华东医药股份有限公司 2018 年第三季度报告正文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人李邦良、主管会计工作负责人李邦良及会计机构负责人(会计主 管人员)马红兰声明：保证季度报告中财务报表的真实、准确、完整。 2 华东医药股份有限公司 2018 年第三季度报告正文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 √ 是 □ 否 追溯调整或重述原因 其他原因 | | 本报告期末 | 上年度末 | | 本报告期末比上年度 | | --- | --- | --- | --- | --- | | | | | | 末增减 | | | | 调整前 | 调整后 | 调整后 | | 总资产（元） | 18,107,222,978.66 | 15,987,106,537.46 ...

Financial Performance - The company's operating revenue for the first half of 2018 was CNY 15,324,950,023.49, representing an increase of 8.76% compared to the same period last year[17]. - The net profit attributable to shareholders was CNY 1,293,389,202.65, reflecting a growth of 24.19% year-on-year[17]. - The net cash flow from operating activities reached CNY 1,070,274,360.77, a significant increase of 287.40% compared to the previous year[17]. - The total assets at the end of the reporting period amounted to CNY 17,088,212,468.47, up by 6.89% from the end of the previous year[17]. - The net assets attributable to shareholders were CNY 8,986,735,179.69, which is a 7.07% increase compared to the previous year[17]. - The basic earnings per share for the reporting period was CNY 0.8870, an increase of 24.19% from the same period last year[17]. - The company achieved operating revenue of CNY 15.33 billion, a year-on-year increase of 8.76%[39]. - The net profit attributable to shareholders reached CNY 1.29 billion, reflecting a growth of 24.19% compared to the previous year[39]. - The core subsidiary, China-US East, reported operating revenue of CNY 4.41 billion, up 26.89%, and net profit of CNY 1.06 billion, an increase of 29.90%[39]. - The gross profit margin for the commercial sector was 7.50%, an increase of 0.32% year-on-year, while the manufacturing sector achieved a gross profit margin of 86.88%, up by 3.26%[49]. Research and Development - Research and development investment increased by 60.56% to CNY 264 million, indicating a strong focus on innovation[46]. - The company plans to initiate domestic clinical registration applications for the oral GLP-1 diabetes drug TTP273 in the second half of the year[41]. - The company is actively expanding its marketing model and has established new research offices in Boston and Silicon Valley[42]. - The company is planning to acquire shares in the UK-listed company Sinclair Pharma plc in the medical aesthetics sector[42]. - The company has made progress in the development of TTP-273, an oral GLP-1 innovative drug, which is expected to submit for clinical trials within 2018[64]. - The company is conducting research on the production of Capofungin and Micafungin, with plans to submit for production approval in Q4 2018[67]. - The company is preparing for the production of clinical samples for various gastrointestinal and cardiovascular drugs, including Omeprazole and Macitentan[68]. - The company has established a logistics distribution system covering the entire province of Zhejiang, with a total warehouse area of 118,000 square meters[31]. Market Strategy and Expansion - The company continues to engage in the production and sales of chemical and traditional Chinese medicine, maintaining its position as a comprehensive pharmaceutical enterprise[25]. - The company aims to enhance its competitive advantage in the fields of anti-tumor drugs, super antibiotics, and cardiovascular drugs through new product development[30]. - The company plans to enhance its marketing efforts and expand its dedicated promotion teams in county-level markets to maintain stable market growth[70]. - The company is focused on expanding its pharmaceutical product offerings and market presence[90]. - The company is exploring potential mergers and acquisitions to enhance its market position[90]. - The company has plans for market expansion and new product development, although specific figures were not disclosed in the report[198]. Financial Position and Liabilities - The total liabilities increased to 7.652 billion RMB from 7.178 billion RMB in the previous year[169]. - The debt-to-asset ratio at the end of the reporting period is 44.78%, a decrease of 0.12% compared to the previous year[159]. - The current ratio is 2.05, down 4.44% from the previous year[159]. - The company obtained bank credit of 7.404 billion RMB during the reporting period, with 812 million RMB utilized and no overdue loans[161]. - The company has maintained a loan repayment rate of 100% during the reporting period[160]. Environmental Compliance - The company is classified as a key pollutant discharge unit by environmental protection authorities[105]. - The total COD discharge was 102.84 tons, with a concentration of 238 mg/l, below the standard of 500 mg/l[105]. - The company reported a total of 964.7 tons of hazardous solid waste disposed of legally, meeting standards[105]. - The company achieved a nitrogen oxide emission of 124.5 mg/m³, below the limit of 400 mg/m³[105]. - The company has no significant environmental protection issues reported during the period[105]. - The wastewater treatment system at Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. has a processing capacity of 800 tons per day after upgrades, operational since 2007[108]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 33,034[139]. - The largest shareholder, China Yuanda Group, holds 41.77% of the shares, amounting to 609,115,131 shares[139]. - The second-largest shareholder, Hangzhou East China Pharmaceutical Group, holds 16.46% of the shares, totaling 240,000,000 shares[139]. - The company has no preferred shares outstanding during the reporting period[145]. - The company paid the third interest payment on its bonds on May 19, 2018, with a total bond balance of 993.95 million yuan[151]. Corporate Governance and Compliance - The company has not experienced any major litigation or arbitration matters during the reporting period[80]. - The company has not implemented any employee stock ownership plans or other incentive measures during the reporting period[82]. - The company has not reported any significant related party transactions during the reporting period[91]. - There were no joint external investment related party transactions during the reporting period[92]. - The company did not have any related party debt or credit transactions during the reporting period[93].